Pulse Biosciences (PLSE) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics:

Revenue: $434,000, a slight increase from $400,000 in Q1 2026.

Cost of Product Revenue: $273,000 for the quarter.

GAAP Net Loss: $24.7 million, compared to $19.2 million in Q2 2025.

Non-GAAP Net Loss: $19.4 million, up from $13.7 million year-over-year.

Total GAAP Costs and Expenses: Increased to $25.7 million from $20.3 million in the prior year, driven by clinical program investments and employee-related expenses.

Cash Position: $101.6 million as of June 30, 2026, up from $68.3 million at the end of Q1 2026, bolstered by $57.5 million raised through an at-the-market (ATM) program.

2Strategic Updates and Business Highlights:

Technology Focus: Continued emphasis on the proprietary nanosecond pulsed field ablation (nsPFA) technology, which is showing promising results in treating atrial fibrillation (AF).

Clinical Progress: Enrollment in the pivotal catheter IDE study is ahead of schedule, with over 82 patients enrolled and a target completion date of early October 2026, three months earlier than initially planned.

Leadership Expansion: Strengthened management team with the addition of a new COO and CMO to enhance operational execution.

Partnerships: New collaboration with the Clayman Thyroid Center to support the Vybrance system for treating benign thyroid nodules.

Regulatory Path: Anticipating CE Mark submission for the nPulse Cardiac Catheter System in the second half of 2026, with potential approval by mid-2027.

3Forward Guidance and Outlook:

Enrollment Expectations: Confident in completing enrollment for the pivotal study by early October 2026, reflecting strong physician enthusiasm and site performance.

Market Development: Plans to begin market development activities as regulatory approvals approach, with a focus on building a sales infrastructure.

Financial Discipline: Expectation to maintain operating expenses in the current range as clinical programs continue to be funded.

4Challenges and Points of Concern:

Increasing Costs: Rising operational costs associated with clinical trials and employee compensation could pressure future profitability.

Market Competition: The need to differentiate from existing AF ablation technologies, particularly as the market becomes more competitive with new entrants.

Regulatory Risks: Potential delays or challenges in obtaining CE Mark and FDA approvals could impact timelines and market entry.

5Notable Q&A Insights:

Enrollment Dynamics: Management confirmed that some sites have reached their patient enrollment caps, which may affect the pace of future enrollments, but new sites are being activated to maintain momentum.

Mapping Integration: Currently, all patients are being enrolled using the EnSite mapping system, with discussions ongoing about potential integration with other systems like CARTO.

Economic Value Proposition: The procedural efficiency and economic benefits of the nsPFA technology are expected to drive adoption, with physicians expressing high satisfaction regarding the speed and effectiveness of procedures.

Future Market Potential: The management highlighted that the technology's ability to deliver superior outcomes could significantly influence market share, despite the need for extensive data to validate efficacy against competitors. Overall, Pulse Biosciences is making significant strides in its clinical programs and financial positioning, but faces challenges related to rising costs and competitive pressures in the medical device market.